My cart
In the shopping cart is not goods, to choose and buy!
  • Product Name
  • Size
  • Quantity
  • Amount
    Selected items : 0 pieces Total : CHECK OUT()
    PF-04929113 (SNX-5422)
    PF-04929113 (SNX-5422)

    Market Price:

    This product is for research use only, not for human use. We do not sell to patients.
    Number: - + Pieces(InventoryPieces)
    InvivoChem Cat #: V0890
    CAS #: 908115-27-5 Purity ≥98%

    Description: PF-04929113 (SNX-5422; PF04929113; PF-4929113) is a potent and selective inhibitor of heat shock protein 90 (HSP90) with potential antineoplastic activity. It inhibits HSP90 with a Kd of 41 nM. PF 04929113 exhibits excellent in vivo antitumor efficacy in fox chase SCID mice bearing MM.1S cells.

    References: J Med Chem. 2009;52(14):4288-305; Blood. 2009;113(4):846-55; Clin Cancer Res. 2011;17(8):2301-13. 

    Related CAS: 1173111-67-5 (mesylate); 908115-27-5 (free base);

    Customer Validation
    Official Supplier of
    • VE
    • OF
    • YALE
    • hhmi
    • 香港大学
    Publications Citing InvivoChem Products
    • Physicochemical and Storage Information
    • Protocol
    • Quality Control Documentation
    • Related Biological Data
    • Customer Review
    Molecular Weight (MW)521.53
    CAS No.908115-27-5 (free base);
    Storage-20℃ for 3 years in powder form
    -80℃ for 2 years in solvent
    Solubility (In vitro)DMSO: 5 mg/mL (9.6 mM)
    Water: <1 mg/mL
    Ethanol: 3 mg/mL (5.2 mM)
    Solubility (In vivo)0.5% CMC+0.25% Tween 80: 25mg/mL  
    SynonymsSNX-5422; PF 4929113; PF04929113; PF 04929113; SNX5422; SNX 5422; PF-04929113; PF4929113; PF-4929113; 

    • Molarity Calculator
    • Dilution Calculator
    • The molarity calculator equation

      Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

      • Mass
      • Concentration
      • Volume
      • Molecular Weight *
      • =
      • ×
      • ×
    • The dilution calculator equation

      Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

      This equation is commonly abbreviated as: C1V1 = C2V2

      • Concentration (start)
      • ×
      • Volume (start)
      • =
      • Concentration (final)
      • ×
      • Volume (final)
      • ×
      • =
      • ×
      • C1
      • V1
      • C2
      • V2
    In Vitro

    In vitro activity: PF-04929113 is a small-molecule Hsp90 inhibitor based on the 6,7-dihydro-indazol-4-one scaffold. PF-04929113 developed by Serenex, converts to SNX-2122, which is the active Hsp90 inhibitor form. PF-04929113 exhibits potent effects on Her-2 stability and causes expected up-regulation of Hsp70. PF-04929113 shows potent antiproliferative activity against a broad range of cancer cell types, e.g. MCF-7 (IC50=16 nM), SW620 (IC50=19 nM), K562 (IC50=23 nM), SK-MEL-5 (IC50=25 nM), and A375 (IC50=51 nM).

    Kinase Assay: Hsp90 from porcine spleen extract is isolated by affinity capture on a purine-affinity media. The Hsp90 loaded media is then challenged with PF-04929113 at a given concentration, ranging from 0.8 to 500 μM, and the amount of Hsp90 liberated at each concentration is determined by Bradford protein assay. The resulting IC50 values are corrected for the ATP ligand concentration and presented as apparent Kd values.

    Cell Assay:  All assays are done in 96-well plates. All cell lines are purchased from ATCC. Proliferation rates are measured by seeding cells (MCF-7, SW620, K562, SK-MEL-5 and A375 cancer cell lines) into 96-well plates, followed by compound addition 24 h later. After addition of PF-04929113, cells are allowed to grow for either an additional 72 or 144 h depending on rate of growth. At harvest, media is removed and DNA content for individual wells is determined using CyQuant DNA dye. Levels of Hsp90 client proteins and phosphor-regulated proteins in A375 are measured by high content analysis (HCA) using an ArrayScan 4.5 instrument after 24 hours of treatment with PF-04929113, followed by methanol fixation. After fixation in 4% PBS-buffered formalin and permeablization with 0.1% TX-100, cells are probed with anti-Her2, antiphospho-S6 (pS6), antipERK, and anti-Hsp70 primary antibodies, followed by TRITC or FITC conjugated secondary antibodies. Nuclei are also stained with Hoechst DNA binding dye. For each well, 250-500 individual nuclei are identified along with the average staining intensity for the client and phospho-proteins for each cell. Average client staining intensities are then calculated for each well.

    In VivoPF-04929113 inhibits human MM cell growth in vivo, and immuno-histochemical analysis shows PF-04929113 significantly inhibits p-ERK and p-Akt in treated mice. Meanwhile, PF-04929113 treatment significantly decreases the percentage of CD31+ cells and MVD, consistent with an inhibitory effect on angiogenesis in vivo. A 50 mg/kg administration of PF-04929113 delivered 3 times per week significantly delays castrate-resistant LNCaP tumor growth and prolongs cancer specific survival. Immuno-histochemical analysis indicates increased SP70 expression, and decreases Ki67, Akt, and AR expression, after treatment with PF-04929113. Inhibition of tumor progression by PF-04929113 may result from a combination of decreased proliferative (reduced Ki67 and Akt expression) or increased apoptosis (increased ApopTag staining) rates.
    Animal modelFox Chase SCID mice bearing MM.1S cells
    Formulation & DosageDissolved in 1% carboxy methylcellulose/0.5% Tween 80 at 10 mg/mL and stored at 4 °C for in vivo study; 20 or 40 mg/kg; oral gavage

    J Med Chem. 2009 Jul 23;52(14):4288-305; Blood. 2009 Jan 22;113(4):846-55; Clin Cancer Res. 2011 Apr 15;17(8):2301-13. 

    These protocols are for reference only. InvivoChem does not independently validate these methods.

    PF-04929113 (SNX-5422)

    PF-04928473 induces degradation of Hsp90 client proteins, inhibits AR transactivation and nuclear translocation, and downregulates AR-regulated genes. Clin Cancer Res. 2011 Apr 15;17(8):2301-13.

    PF-04929113 (SNX-5422)

    PF-04929113 significantly delays castrate-resistant LNCaP tumor growth and prolongs cancer specific survival. Clin Cancer Res. 2011 Apr 15;17(8):2301-13.

    PF-04929113 (SNX-5422)

    Serum PSA changes in PF-04929113-treated mice do not correlate to suppression of tumor volume progression. Clin Cancer Res. 2011 Apr 15;17(8):2301-13.


      Home Prev Next Last page / pices


      Your information is safe with us. * Required Fields.
      Products are for research use only;  We do not sell to patients
      Tel: 1-708-310-1919
      Fax: 1-708-557-7486
      Subscribe to our E-newsletter
      • Name*
      • *
      • E-mail*
      • *
      • instructions:
      • *
      Copyright 2020 InvivoChem LLC | All Rights Reserved
      Do you confirm the receipt?